Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer

Published:2018-02 Issue: Volume:90 Page:153-155
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Miles David,Cameron David,Hilton Magalie,Garcia Josep,O'Shaughnessy Joyce

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference8 articles.

1. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation;Miles;Eur J Cancer,2017

2. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

4. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

5. Detecting an overall survival benefit that is derived from progression-free survival;Broglio;J Natl Cancer Inst,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial;Clinical Cancer Research;2023-11-08

2. Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies;Breast Cancer;2022-09-03

3. VEGF-Independent Angiogenic Factors: Beyond VEGF/VEGFR2 Signaling;Journal of Vascular Research;2022

4. First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study;The Breast;2021-12

5. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids;PLOS ONE;2021-07-07